You are here

AbbVie

AbbVie bows to pressure to keep cheaper Imbruvica formula on the market

AbbVie bows to pressure to keep cheaper Imbruvica formula on the market

Fierce Pharma

Flag link:

AbbVie's elagolix could put pressure on budgets, ICER estimates

AbbVie's elagolix could put pressure on budgets, ICER estimates

Biopharma Dive

Flag link:

21% Of AbbVie Inc (ABBV) Shareholders Want To Know How Drug Pricing Is Integrated Into Incentive Programs

21% Of AbbVie Inc (ABBV) Shareholders Want To Know How Drug Pricing Is Integrated Into Incentive Programs

Value Walk

Flag link:

Better together? AbbVie’s Humira and Pfizer’s Lyrica again outspend other brands

Better together? AbbVie’s Humira and Pfizer’s Lyrica again outspend other brands

Fierce Pharma

Flag link:

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

CP Wire

Flag link:

AbbVie Submits Marketing Application to the European Medicines Agency for Risankizumab in Plaque Psoriasis

Flag link:

AbbVie's First Quarter: Trying to Replace Humira Sales

AbbVie's First Quarter: Trying to Replace Humira Sales

Yahoo/Motley Fool

Flag link:

The hepatitis C duopoly

The hepatitis C duopoly

Axios

Gilead Sciences

Flag link:

AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback

AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback

Marketwatch

Flag link:

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study

CP Wire

rheumatoid arthritis

clinical trials

Flag link:

This Small Biotech Is Building on a Surprising Success

This Small Biotech Is Building on a Surprising Success

Motley Fool

Enanta Pharmaceuticals

Flag link:

Immunotherapies, biosimilars to dominate next week of earnings

Immunotherapies, biosimilars to dominate next week of earnings

Biopharma Dive

Bristol-Myers Squibb

Vertex Pharmaceuticals

Flag link:

Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira in Europe

Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira in Europe

CP Wire

Flag link:

With study success, AbbVie's arthritis hopeful looks to be a safer bet

With study success, AbbVie's arthritis hopeful looks to be a safer bet

Biopharma Dive

rheumatoid arthritis

clinical trials

Flag link:

Elagolix review extended

Flag link:

FDA Requires More Time to Review Abbvie and Neurocrine Endometriosis Drug Elagolix

FDA Requires More Time to Review Abbvie and Neurocrine Endometriosis Drug Elagolix

CP Wire

Flag link:

$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023

$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023

Endpoints

Flag link:

Which Big Pharma CEOs Least Deserved Their Big Pay Increases?

Which Big Pharma CEOs Least Deserved Their Big Pay Increases?

Motley Fool

Bristol-Myers Squibb

Gilead Sciences

Flag link:

Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report

Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report

Fierce Pharma

Flag link:

When Will They Learn? 4 Huge Biotech Blowups

When Will They Learn? 4 Huge Biotech Blowups

Motley Fool

drug manufacturing

Cubist Pharmaceuticals

Flag link:

Pages